These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 30587719)

  • 1. [Cancer Treatment-Induced Bone Loss(CTIBL)].
    Fukumoto S; Matsumoto T
    Gan To Kagaku Ryoho; 2018 Dec; 45(12):1685-1689. PubMed ID: 30587719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody.
    von Moos R; Costa L; Gonzalez-Suarez E; Terpos E; Niepel D; Body JJ
    Cancer Treat Rev; 2019 Jun; 76():57-67. PubMed ID: 31136850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Encounter of cancer cells with bone. Cancer treatment-induced bone loss : CTIBL].
    Takahashi S
    Clin Calcium; 2011 Mar; 21(3):447-53. PubMed ID: 21358067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer treatment-induced bone loss: pathophysiology and clinical perspectives.
    Brufsky AM
    Oncologist; 2008 Feb; 13(2):187-95. PubMed ID: 18305064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Denosumab for cancer-related bone loss.
    Dell'Aquila E; Armento G; Iuliani M; Simonetti S; D'Onofrio L; Zeppola T; Madaudo C; Russano M; Citarella F; Ribelli G; Pantano F; Vincenzi B; Tonini G; Santini D
    Expert Opin Biol Ther; 2020 Nov; 20(11):1261-1274. PubMed ID: 32835531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
    Brufsky A
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of bone loss due to endocrine therapy during cancer treatment.
    Khan MI
    Osteoporos Int; 2023 Apr; 34(4):671-680. PubMed ID: 36656338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of cancer treatment-induced bone loss (CTIBL) in patients with breast cancer or prostate cancer.
    Takahashi S
    J Bone Miner Metab; 2023 May; 41(3):307-316. PubMed ID: 37036530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of bone health in patients with cancer: a survey of specialist nurses.
    Drudge-Coates L; van Muilekom E; de la Torre-Montero JC; Leonard K; van Oostwaard M; Niepel D; Jensen BT
    Support Care Cancer; 2020 Mar; 28(3):1151-1162. PubMed ID: 31203509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer treatment-induced bone loss in patients with breast or prostate cancer.
    Maxwell C; Viale PH
    Oncol Nurs Forum; 2005 May; 32(3):589-603. PubMed ID: 15897934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cancer treatment-induced bone loss. Treatment for breast cancer].
    Yamada K; Kohno N
    Clin Calcium; 2008 Apr; 18(4):507-17. PubMed ID: 18379033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant therapy with bone-targeted agents.
    Wilson C; Coleman RE
    Curr Opin Support Palliat Care; 2011 Sep; 5(3):241-50. PubMed ID: 21785355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results.
    Nakatsukasa K; Koyama H; Ouchi Y; Ono H; Sakaguchi K; Matsuda T; Kato M; Ishikawa T; Yamada K; Yoshimura M; Koizumi K; Sakurai T; Shigematsu H; Takahashi S; Taira S; Suzuki M; Narui K; Niikura N; Hasegawa Y; Miura D; Konishi E; Taguchi T;
    Breast Cancer; 2019 Jan; 26(1):106-112. PubMed ID: 30054855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer-treatment-induced bone loss, part 2.
    Michaud LB; Goodin S
    Am J Health Syst Pharm; 2006 Mar; 63(6):534-46. PubMed ID: 16522890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of bisphosphonates in the adjuvant setting for breast cancer.
    Reeder JG; Brufsky AM
    Oncology (Williston Park); 2010 May; 24(6):462-7, 475. PubMed ID: 20568587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Denosumab and the current status of bone-modifying drugs in breast cancer.
    Lee BL; Higgins MJ; Goss PE
    Acta Oncol; 2012 Feb; 51(2):157-67. PubMed ID: 22150116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic approaches for protecting bone health in patients with breast cancer.
    Lüftner D; Niepel D; Steger GG
    Breast; 2018 Feb; 37():28-35. PubMed ID: 29073497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toward new horizons: the future of bisphosphonate therapy.
    Lipton A
    Oncologist; 2004; 9 Suppl 4():38-47. PubMed ID: 15459428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moving into the future: treatment of bone metastases and beyond.
    Hortobagyi GN
    Cancer Treat Rev; 2005; 31 Suppl 3():9-18. PubMed ID: 16249057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonates and other bone agents for breast cancer.
    Wong MH; Stockler MR; Pavlakis N
    Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.